Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?

Subodh Verma; Deepak L. Bhatt

doi:https://doi.org/10.1016/j.cjca.2019.11.011

doi.org/10.1016/j.cjca.2019.11.011

Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?

,

Canadian Journal of Cardiology6.20

Volume: 36, Issue: 1, Pages: 24 - 26

Published: Jan 1, 2020

Abstract

Inflammation has emerged as an important pathophysiologic mechanism of atherosclerosis.1Verma S. Szmitko P.E. Ridker P.M. C-Reactive protein comes of age.Nat Clin Pract Cardiovasc Med. 2005; 2: 29-36Google Scholar, 2Blankstein R. Libby P. Bhatt D.L. Arterial inflammation: the heat before the storm.J Am Coll Cardiol. 2019; 73: 1383-1385Google Scholar, 3Libby P. Bhatt D.L. di Carli M. Fluorodeoxyglucose uptake in atheroma: not so simple.J Am Coll...